Search clinical trials for: Inetetamab, pyrotinib, chemotherapy

Total 2691 results

Fujian Medical University

Not yet recruiting

A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

HER2-positive Recurrent/Metastatic Breast Cancer
Sun Yat-sen University

Recruiting

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Recruiting

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

Breast Cancer

China
Peking Union Medical College

Not yet recruiting

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Breast Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Breast Neoplasms

China
Wang Ouchen

Recruiting

A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer (neoPICD)

Breast Neoplasm Female

China
Zhiyong Yu

Not yet recruiting

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
Liaoning Tumor Hospital & Institute

Completed

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

HER2-positive Metastatic Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Breast Neoplasms

China
Zhiyong Yu

Not yet recruiting

RWS of Inetetamab HER2 Positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer
Shu-Zhong Cui
Guangdong Provincial Hospital of Traditional Chinese Medicine; Chinese PLA... and other collaborators

Unknown

Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer

Gastric Cancer | Peritoneal Carcinomatosis

China
Hunan Cancer Hospital
Hunan Medical University General Hospital

Not yet recruiting

A Real-world Study of Inetetamab for First-line Treatment of MBC

Breast Cancer | Real-world Study
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (HER2-VIP)

HER2-positive Advanced Breast Cancer

China
Fudan University

Recruiting

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Metastatic Breast Cancer | HER2-positive Breast Cancer

China
Henan Cancer Hospital

Active, not recruiting

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

HER2 Positive Metastatic Breast Cancer

China
Peking University

Recruiting

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

HER2-positive Breast Cancer

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

Breast Cancer

China
Peking Union Medical College

Unknown

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Breast Cancer | HER2 Gene Mutation

China
Tongji University

Unknown

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Non Small Cell Lung Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (DAP-Her-01)

Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Non Small Cell Lung

China
RemeGen Co., Ltd.

Not yet recruiting

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Non-small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; First Affiliated Hospital of Zhejiang University; Sir... and other collaborators

Unknown

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

Colorectal Cancer

China
The First Affiliated Hospital with Nanjing Medical...
First Affiliated Hospital of Wenzhou Medical University

Recruiting

A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

Breast Cancer

China
xuexin he

Not yet recruiting

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer (SHERO)

HER2-positive Breast Cancer
Hengrui Therapeutics, Inc.

Unknown

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Breast Cancer | Gastric Cancer | NSCLC | Solid Tumors

United States
Sun Yat-sen University

Recruiting

Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer (Increase)

Breast Cancer

China
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Biyun Wang, MD

Completed

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

HER2-positive Breast Cancer

China
Fudan University
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Advanced/ Metastatic Her-2 Positive Breast Cancer

China
Taizhou Hospital

Recruiting

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

Breast Cancer

China
Sun Yat-sen University

Recruiting

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Breast Cancer | Breast Diseases | HER2-positive Breast Cancer | Vinorelbine | Pyrotinib

China
Kyungpook National University Hospital
National Cancer Center, Korea; Chonnam National University Hospital; Daegu Catholic... and other collaborators

Unknown

Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer (EPIC-GC)

Advanced Gastric Cancer With Serosal Invasion

Korea, Republic of
RenJi Hospital

Recruiting

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer (CORINNE-PI)

Breast Cancer Invasive

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
RenJi Hospital

Recruiting

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer (ATP)

Locally Advanced Breast Cancer

China
RenJi Hospital

Active, not recruiting

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer (NeoATP)

Breast Cancer Female

China
The First Affiliated Hospital with Nanjing Medical...

Active, not recruiting

Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

HER2-positive Breast Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
Peking Union Medical College Hospital

Recruiting

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Fudan University

Recruiting

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Effect of Drug | Gastrointestinal Tumor

China
Fudan University

Recruiting

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Breast Cancer Stage I

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer

HER2 Positive Gastric Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Breast Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Breast Neoplasm Female

3

Subscribe